This is a routine disease-awareness press release with no financial or regulatory catalyst. Monitor for future pipeline updates or regulatory milestones for BridgeBio's ATTR-CM program, but no near-term stock-moving event is indicated.
Price Chart
Executive Summary
BridgeBio Pharma announced a nationwide education campaign to raise awareness of ATTR cardiac amyloidosis (ATTR-CM), including a YouTube premiere on October 6 featuring cultural and medical leaders. The initiative is a disease-awareness effort, not a regulatory filing or financial event, and does not disclose any financial terms, revenue, or pipeline milestones.
Key Facts
- Nationwide education campaign for ATTR-CM awareness, starting with a YouTube premiere on October 6, 2026 at 6:00 pm EDT.
- Partners include Association of Black Cardiologists, National Minority Quality Forum, 100 Black Men of the Bay Area, and National Medical Association.
- Approximately 1 in 25 Black Americans carries the V142I (V122I) variant associated with ATTR-CM.
- No financial terms, revenue, guidance, or pipeline data disclosed in the press release.
Financial Impact
No financial impact disclosed; the press release describes a disease-awareness initiative with no associated revenue, costs, or deal value.
Risk Factors
- No material financial or regulatory catalyst; the campaign is unlikely to affect near-term stock price.
- ATTR-CM awareness campaigns are common and do not differentiate BridgeBio from competitors.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3374976 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G | $68.25 | awaiting T+20 | — | $69.37 (+1.64%) |
Oct 22, 2026 5d ago | Press Release | $68.12 | awaiting T+20 | — | $69.37 (+1.84%) |
Oct 13, 2026 14d ago | 8-K | $63.30 | awaiting T+20 | — | $69.37 (+9.59%) |
Oct 6, 2026 21d ago | Press Release | $66.96 | awaiting T+20 | — | $69.37 (+3.60%) |
Oct 5, 2026 22d ago | Press Release | $66.96 | awaiting T+20 | — | $69.37 (+3.60%) |
Oct 5, 2026 22d ago | Press Release | $66.14 | awaiting T+20 | — | $69.37 (+4.88%) |
Sep 18, 2026 5w ago | Press Release | $66.58 $67.94 | ▲ +2.04% | ▲ +2.95% | $69.37 (+4.19%) |
Aug 31, 2026 8w ago | 8-K | $76.59 $65.97 | ▼ −13.87% | ▼ −13.68% | $69.37 (−9.43%) |
Aug 26, 2026 8w ago | Press Release | $79.37 $66.28 | ▼ −16.49% | ▼ −16.72% | $69.37 (−12.60%) |
Aug 22, 2026 9w ago | Institutional Cluster | $81.07 $69.23 | ▼ −14.60% | ▼ −15.92% | $69.37 (−14.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers